Clinical trial NCT04910893: Cytokine Adsorption in Severe, Refractory Septic Shock
Official title: Cytokine Adsorption in Severe, Refractory Septic Shock
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Septic Shock
Cytokine Storm
Keywords: Septic Shock
Cytokine Adsorption
Hemadsorption
extracorporeal removal
Lead sponsor: University of Zurich
Sponsor class: OTHER
Collaborators: name: CytoSorbents Europe GmbH
First posted: 2021-06-02
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prospective interventional study with comparative matched septic shock cohort
Primary purpose: TREATMENT

Brief summary: Septic shock and the underlying dysregulated inflammatory host-response remain a major contributor to mortality in critically ill patients. Cytokine adsorption represents an attractive approach to the treatment of septic shock. Nevertheless, its effect on circulating cytokine levels, as well as on the course of disease remains largely unassessed.

Detailed description: Cytokine-release plays an important role in the physiology of immune response to pathologic influences by recruiting immune cells to the pathogenic loci, be they of infectious or of non-infectious nature. Once at the focus, the activated immune cells can in turn release more cytokines if a more extensive immune response is needed. This extremely important mechanism for the organism, can however become pathological if the positive feedback loop between immune cells and cytokines, for any reason, overshoots in form of a so called cytokine storm and substantial amounts of released cytokines gain a systemic influence. The acute complication of this immune over-reaction is a SIRS, which can critically escalate into a potentially lethal multiple organ dysfunction syndrome, thus requiring immediate intensive care treatment.

It is, having this framework in mind, the reason why the CytoSorb-Adsorber has been developed as a new therapeutic milestone. Essentially a haemoperfusion-filter, which through its layering with polymer beads (Divinylbenzene/ Polyvinylpyrrolidone) can adsorb cytokines as well as multiple inflammatory mediators and thus effectively remove them from the bloodstream, reducing their possible systemic influence and hence improving the outcome for patients being treated with it.

The CytoSorb-Adsorber is an already CE-approved product, which has demonstrated its capacity to significantly reduce cytokine-levels such as IL-6, IL-8, IL-10, TNFα, HMGB-1, IL-1ra in a variety of pre-clinical studies. As well as in a clinical randomised multicentre study, which tested the CytoSorb-Adsorber on a cohort of ALI/ ARDS and severely septic/ septically shocked patients. The results of the later study can be very positively assessed, first of all and most importantly showing, that no security concerns had to be had in regard to the haemoperfusion-filter, as no adverse-effects attributable to the device were found. And further, by proving an effect on systemic cytokine-levels in form of a significant reduction in IL-6, IL-8, MCP-1 and IL-1ra, as well as a reduction in mortality of those patients with high initial cytokine levels, effectively reducing the 60 day mortality rate from 60% to 17% in a pool of 14 patients.

With the intention to further elucidate the usefulness and clinical importance of this device this study proposes a prospective recruitment of patients in severe refractory septic shock to test the efficiency of this device.

Eligibility criteria: Inclusion Criteria:

Patients diagnosed septic shock in the 24 hours ensuing diagnosis:

(I) severe, refractory septic shock defined as:

1. an acute SOFA score increase ≥2 points consequent to a presumed or proven infection
2. volume resuscitation of at least 30ml/kg in the last 24 hours
3. a Vasopressor Dependency Index11 (VPI) above or equal to 3
4. a persistently elevated serum lactate level \>2mmol/l (II) Interleukin-6 levels equal or above 1000 ng/l (III) were above 18 years of age.

Exclusion Criteria:

1. Contraindication on ethical grounds
2. child bearing or breastfeeding women
3. terminal patients
4. human immunodeficiency virus with a CD4 cell count \<0.2 106/l
5. allergy to Polystyrene/ Divinylbenzene, Polycarbonate, Polypropylene, Silicon or Polyester
6. need for extra-corporeal membrane oxygenation
7. no given consent.

Primary outcomes:
measure: Change in circulating Interleukin-6 levels over time
timeFrame: Mixed Model Assessment at timepoints 0, 24, 48, 72 hours
measure: Change in Vasopressor requirements over time
timeFrame: Mixed Model Assessment at timepoints 0, 2, 4, 8, 12 , 24, 48, 72 hours
measure: Cumulative intensive care mortality at 30 days
timeFrame: 30 days post fulfillment of inclusion criteria
Secondary outcomes:
measure: Change in C-reactive protein levels over time
timeFrame: Mixed Model Assessment at timepoints 0, 24, 48, 72 hours
measure: Change in Procalcitonin levels over time
timeFrame: Mixed Model Assessment at timepoints 0, 24, 48, 72 hours
measure: Change in SOFA Score over time
timeFrame: Mixed Model Assessment at timepoints 0, 24, 48, 72 hours
measure: Change in arterial lactate levels over time
timeFrame: Mixed Model Assessment at timepoints 0, 2, 4, 8, 12 , 24, 48, 72 hours
measure: Change in cardiac index over time
timeFrame: Mixed Model Assessment at timepoints 0, 2, 4, 8, 12 , 24, 48, 72 hours
measure: Change in Extra Vascular Lung Water Index over time
timeFrame: Mixed Model Assessment at timepoints 0, 24, 48, 72 hours
measure: Change in daily Infused Volume over time
timeFrame: Mixed Model Assessment at timepoints 0, 24, 48, 72 hours
measure: Change in PaO2/ FiO2 Ratio over time
timeFrame: Mixed Model Assessment at timepoints 0, 2, 4, 8, 12 , 24, 48, 72 hours
measure: Change in Serum Albumin levels over time
timeFrame: Mixed Model Assessment at timepoints 0, 24, 48, 72 hours
measure: Change in Bilirubin levels over time
timeFrame: Mixed Model Assessment at timepoints 0, 24, 48, 72 hours
Other outcomes:
Locations:
Study officials:
affiliation: Medizinische Intensivstation D-HOER 27, UniversitatsSpital Zürich
name: Marco Maggiorini, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med. 2008 Jul;26(6):711-5. doi: 10.1016/j.ajem.2007.10.031.
citation: Taniguchi T. Cytokine adsorbing columns. Contrib Nephrol. 2010;166:134-141. doi: 10.1159/000314863. Epub 2010 May 7.
citation: Morris C, Gray L, Giovannelli M. Early report: The use of Cytosorb haemabsorption column as an adjunct in managing severe sepsis: initial experiences, review and recommendations. J Intensive Care Soc. 2015 Aug;16(3):257-264. doi: 10.1177/1751143715574855. Epub 2015 Mar 18.
citation: Rimmele T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care. 2011;15(1):205. doi: 10.1186/cc9411. Epub 2011 Feb 16.
citation: Reiter K, Bordoni V, Dall'Olio G, Ricatti MG, Soli M, Ruperti S, Soffiati G, Galloni E, D'Intini V, Bellomo R, Ronco C. In vitro removal of therapeutic drugs with a novel adsorbent system. Blood Purif. 2002;20(4):380-8. doi: 10.1159/000063108.
citation: Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med. 2004 Mar;32(3):801-5. doi: 10.1097/01.ccm.0000114997.39857.69.
citation: Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med. 2008 May;36(5):1573-7. doi: 10.1097/CCM.0b013e318170b9a7.
citation: D Schädler, C Porzelius, A Jörres, G Marx, A Meier-Hellmann, C Putensen, M Quintel, C Spies, C Engel, NWeiler, M Kuhlmann. A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients. Critical Care 2013, 17(Suppl 2):P62 (19 March 2013).